Oracle Runs

Oracle findings and outcome history for A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT (NCT05198323).

Runs

Findings

Latest Run

Apr 6, 2026, 2:57 PM

All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial NCT05198323 (LT3001-203, Phase 2 AIS EVT) remains recruiting per ClinicalTrials.gov, with primary completion estimated March 2026. No public readout or results reported for this specific trial. Positive readouts cited for other LT3001 Phase 2 trials (e.g., LT3001-202 China, LT3001-205 global) do not cover this exact EVT study.

Found Apr 6, 2026, 2:59 PMReviewed Apr 6, 2026, 3:00 PM

ClinicalTrialsclinicaltrials.gov

A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT

Status: Recruiting. Estimated Primary Completion Date: March 31, 2026. No results posted.

Web Searchprnewswire.comOct 28, 2025, 4:00 AM

LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001 Phase 2b Clinical Trial

Positive results from Phase 2b LT3001-202 (China) met primary safety endpoint. Global LT3001-205 also met safety. No mention of NCT05198323/LT3001-203.

NO_DECISIONDismissed75% confidenceGrok 4.20 (xAI)

Will the results be positive?

The queried trial (NCT05198323, Phase 2, LT3001 + EVT in AIS, primary endpoint sICH/NIHSS deterioration within 24h) remains recruiting with estimated completion 2026-03-31. No results or public readout found for this exact protocol. Positive readouts refer to other Phase 2 trials (e.g., LT3001-202/NCT05686642 in non-EVT moderate AIS and LT3001-205), which are not trial-specific to this one.

Found Apr 6, 2026, 2:10 PMReviewed Apr 6, 2026, 2:19 PM

ClinicalTrialsclinicaltrials.gov

A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT

Current status: Recruiting. Estimated primary completion: 2026-03-31. Primary endpoint: occurrence of symptomatic intracranial hemorrhage or NIHSS deterioration ≥4 within 24h.

Web Searchprnewswire.comOct 28, 2025, 12:00 AM

LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE

Positive results from China-based LT3001-202 Phase 2b (met primary endpoint; functional improvements). Presented at WSC 2025. Not the EVT trial.

Web Searchneurologylive.comFeb 19, 2026, 12:00 AM

Neuroprotective Agent LT3001 Heads to Phase 3 Study Following Positive Phase 2 Trials in Acute Ischemic Stroke

Positive Phase 2 results from two trials in disabling AIS; advances to Phase 3. References non-EVT studies.

NO_DECISIONDismissed90% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov still lists this study as recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM

ClinicalTrialsclinicaltrials.govJun 5, 2025, 12:00 AM

Study Details | NCT05198323 | ClinicalTrials.gov

ClinicalTrials.gov lists recruiting; primary completion 2026-03-31; hasResults=false on the latest posted update.

NO_DECISIONDismissed96% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No exact-trial public readout found for NCT05198323/LT3001-203. The registry still shows this Phase 2 EVT study as recruiting with no results posted, and sponsor materials describe LT3001-203 as still enrolling/ongoing rather than reporting trial-specific efficacy or a clear positive/negative outcome.

Found Apr 3, 2026, 4:31 PMReviewed Apr 3, 2026, 4:46 PM

ClinicalTrialsclinicaltrials.gov

Study Details | NCT05198323 | A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT

ClinicalTrials.gov lists NCT05198323 (LT3001-203) as Phase 2, recruiting, with estimated primary completion 2026-03-31 and 'No Results Posted.'

Sponsorlumosa.com.tw

Lumosa Therapeutics investor presentation

Sponsor slide deck labels LT3001-203 as 'P2 (US, TW, n=24, enrolling)' and an exploratory thrombectomy-combination study, indicating no completed exact-trial readout yet.

NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No clear public readout for this exact Phase 2 trial (LT3001-203 / NCT05198323). Sponsor materials list LT3001-203 as ongoing, while the public positive Phase 2 announcements cite other studies (LT3001-202 and LT3001-205), not this EVT trial.

Found Apr 1, 2026, 8:22 PMReviewed Apr 1, 2026, 8:24 PM

Sponsorlumosa.com.tw

LT3001 pipeline page

Sponsor pipeline lists Phase 2 LT3001-203 as 'Multiple dose with thrombectomy on AIS patient' in the USA/Taiwan with status 'Ongoing.'

Sponsorlumosa.com.twOct 28, 2025, 12:00 AM

Lumosa Share Positive P2 Trial Results

Sponsor’s positive Phase 2 announcement is for LT3001-202 and LT3001-205, reporting these studies met safety endpoints and showed efficacy trends; it does not report LT3001-203 results.

Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.